#BiotechStocks
LightNews LightNews
vanjohn10.bsky.social
AEON Biopharma CEO Rob Bancroft gives a Botox history lesson.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/rOo-i...
History of Botox
YouTube video by Unboxing Biotech
youtube.com
November 14, 2026 at 9:50 PM
vanjohn10.bsky.social
AEON Biopharma CEO Rob Bancroft shares some of the tools the FDA is using to evaluate biosimilarity.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/zT65k...
Tools to Evaluate Biosimilarity
YouTube video by Unboxing Biotech
youtube.com
November 9, 2026 at 11:34 PM
theminingnews.bsky.social
🚀 Zacks Small Cap Research - PLX: Elfabrio Estimates Up, Again
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-plx-elfabrio-estimates-up-again/
#PLX #Prot#PLXB#ProtalixBioTherapeutics #Elfabrio##ElelysoA#PRX115##ACR2026##Biotecht#BiotechStocks #SmallCape#E/hashtag/StockResearch" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#StockResearch
November 12, 2026 at 2:06 AM
vanjohn10.bsky.social
AEON Biopharma CEO Rob Bancroft explains the financial difficulties therapeutic providers face when using Botox.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/GiXzo...
Why Doctors Barely Profit from Botox
YouTube video by Unboxing Biotech
youtube.com
November 5, 2026 at 12:29 AM
vanjohn10.bsky.social
AEON Biopharma CEO Rob Bancroft discusses the FDA-requested bridging studies for the head to head trials between ABP-450 and Botox.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/v9fel...
Botox Bridging Studies
YouTube video by Unboxing Biotech
youtube.com
October 31, 2026 at 8:12 PM
vanjohn10.bsky.social
AEON Biopharma CEO Rob Bancroft summarizes ABP-450's analytical studies and other work completed so far to support biosimilarity.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/m05Lt...
ABP-450 Next Studies
YouTube video by Unboxing Biotech
youtube.com
October 26, 2026 at 12:24 AM
vanjohn10.bsky.social
AEON Biopharma CEO Rob Bancroft underscores FDA feedback from Type 2a and 2b meetings.
#$AEON #BiotechStocks #Investing #BioTech #Biosimilars #Investors #ABP450 #BotoxBiosimilar #FDAApproval
youtube.com/shorts/WzoC-...
AEON s FDA Meetings
YouTube video by Unboxing Biotech
youtube.com
October 23, 2026 at 9:54 PM
vanjohn10.bsky.social
Zacks' Senior Life Sciences Analyst John Vandermosten initiates on AEON Biopharma with a $2.00 price target.
#$AEON: Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar:
s27.q4cdn.com/906368049/fi...
#BiotechStocks #Biosimilars #Biologics #BotulinumToxin #ABP450 #MarketNews
October 15, 2026 at 7:23 PM
biotechstockdaily.bsky.social
Zymeworks has completed its acquisition of Theravance Biopharma, expanding its commercial portfolio through YUPELRI profit-share revenue and additional royalty assets.

#Biotech #BiotechStocks #Pharma

Disclaimer: This is NOT a financial advice
September 30, 2026 at 3:00 PM
biotechstockdaily.bsky.social
Oruka reports deeper Week 28 psoriasis responses for
ORKA-001 following two induction doses. The results come from a small Phase 2a trial.

#Biotech #BiotechStocks #ClinicalTrials #Phase2

Disclaimer: This is NOT a financial advice
September 29, 2026 at 6:27 AM
wsuearth.bsky.social
4. Monopar Therapeutics (MNPR)
+1,513% 🧬
A small-cap biotech working on cancer therapeutics. A sudden spike followed after positive Phase II trial results for its lead drug targeting aggressive cancers.
#CancerResearch #BiotechStocks
May 28, 2025 at 10:11 AM
biznizinsiderph.bsky.social
Three cancer drug programs advanced this week, marking notable milestones in ongoing oncology research and development efforts. #$IBB #$XBI #BiotechStocks #Healthcare Read the analysis: aktiego.com/weekly-marke...
Three Cancer Drug Programs Advanced This Week and Nobody Noticed - AktieGo
MAIA Biotechnology got FDA clearance to open US enrollment for its Phase 2 lung cancer trial on June 3. ADC Therapeutics released Phase 3 data confirming ZYNLONTA extends progression-free survival in ...
aktiego.com
June 20, 2026 at 8:50 AM
biznizinsiderph.bsky.social
From PROTAC breakthroughs to the GLP-1 war, biotech investors had plenty to watch this week. See the trends driving the sector higher. aktiego.com/weekly-marke...
#BiotechStocks #FDA #$NVO #$LLY
Biotech & Health Weekly: The Week a New Drug Class Got Approved - AktieGo
The FDA approved the world's first PROTAC drug. Eli Lilly posted its most dominant GLP-1 quarter yet. Novo Nordisk's Wegovy pill hit $355M in Q1. Biotech M&A is running at its fastest pace since 2018....
aktiego.com
May 13, 2026 at 4:03 PM
biznizinsiderph.bsky.social
FDA IND approved: Mabwell’s first-in-class 9MW5211 moves forward in IBD and MS indications. Strong preclinical data behind it. Check the full article: aktiego.com/sectors/biot... #LifeSciences #BiotechStocks $MABWELL
Mabwell Receives FDA IND Clearance for Novel IBD Antibody 9MW5211 - AktieGo
Mabwell receives FDA IND clearance for 9MW5211 in IBD, a novel depleting antibody and the world's first clinical-stage drug candidate targeting its specific immune pathway.
aktiego.com
May 12, 2026 at 4:58 PM
biznizinsiderph.bsky.social
Fixing Ozempic’s Biggest Flaw
#$VNDA launches trial for NEREUS (tradipitant) — 50% vomiting reduction in accelerated GLP-1 dosing. Perfect complement to Novo & Lilly. Bullish setup with no direct competition:
aktiego.com/sectors/biot...
#VNDA #GLP1 #BiotechStocks
The Missing Piece of the Ozempic Revolution Just Got a Clinical Trial - AktieGo
Vanda Pharmaceuticals has started a clinical trial of NEREUS for GLP-1 induced vomiting. Phase 2 showed a 50% reduction. Here's what it means for Ozempic patients.
aktiego.com
April 9, 2026 at 10:32 AM
gunpowderindia.bsky.social
Kalyan Ram Mangipudi as Whole-time Director for 5 years at a consolidated salary of ₹1,00,000 per month; (ii) appointment of prom...

🚀 Free alerts → https://gunpowderalerts.in/go?utm_source=bluesky&utm_medium=social&utm_campaign=high_priority_filing
#StockMarket #BiotechStocks #CorporateGovernance
June 12, 2026 at 10:47 AM
bullmarketreport.bsky.social
More Insights : BullMarket.Substack.com

Website : BullMarket.com

#RXRX #BiotechStocks #AIDrugDiscovery #TechBio #BullMarketReport
April 23, 2025 at 4:49 PM
postgoo.bsky.social
Principal Financial Group offloaded 32.8% of its $GH shares in Q3. This institutional move sparks questions for the precision oncology firm. What's next for Guardant Health?

#Google_trends #GuardantHealth #BiotechStocks #InvestmentNews
Principal Financial Dumps Guardant Health ($GH) Shares!
Principal Financial Group offloaded 32.8% of its $GH shares in Q3. This institutional move sparks questions for the precision oncology firm. What's next for Guardant Health?
www.marketbeat.com
February 12, 2026 at 5:10 PM
mmnewsletter.bsky.social
A Biotech Stock With First-Mover Edge

#BiotechStocks #FDAApproval #LungHealth
August 12, 2025 at 9:11 PM
usstockpros.bsky.social
Genprex (GNPX) to present data at the ADA 85th Scientific Sessions this June — a potential catalyst for biotech exposure.

⸻

#BiotechStocks #GNPX #HealthTech
March 25, 2025 at 12:32 PM
handle.invalid
🚀 Exciting times for #TNYA! Successful Phase 2 trial results could spark volatility. Watch for a breakout above $0.68, targeting $0.72 & $0.75. RSI near oversold & MACD bearish, so stay cautious. Biotech buzz is real, but keep an eye on regulatory news! #FeetrAI #BiotechStocks
August 9, 2025 at 1:00 PM
handle.invalid
Bearish vibes for #XLO! 📉 Trading at $0.6798, it's oversold with negative momentum. Short position alert: Enter around $0.68, target $0.65 & $0.60, stop loss at $0.70. Caution: Phase 2 trial news could shake things up! #FeetrAI #StockAnalysis #BiotechStocks
February 3, 2025 at 5:00 PM
newsfile.bsky.social
Advancements in Novel Immunotherapeutics in The Oncology Battle @Investorideas #biotechstocks #cancer #Immunotherapeutics #medicaltech #oncology #Publishing #NASDAQ #Investing
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications.Advancements in Novel Immunotherapeutics in The Oncology BattleTo view an enhanced...
dlvr.it
March 24, 2026 at 2:30 PM